The Diabetes Staging System (DSS): A Pilot Study Assessing Feasibility, Provider Engagement and Implementation Challenges of a Novel Staging System for Type 2 Diabetes
Open Access
- 1 April 2026
- journal article
- research article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-13
Abstract
Introduction and Objective: Type 2 diabetes (DM2) currently lacks a standardized staging system that can be used to predict survival and guide providers towards guideline concordant care much like TNM staging does for cancer. We conducted a pilot study to assess the feasibility, provider engagement and implementation challenges of the DSS and examined if guideline concordant care improved especially SGLT2i/GLP-1a use in Veterans DM2 patients with cardiorenal disease. Methods: A 6-month pilot study implemented DSS in VA primary care clinics between December 2023–September 2024. Study visits were at baseline and 6 months. Primary outcome: the initiation of SGLT2i/GLP-1a in Veteran DM2 patients with CVD/CKD compared to baseline. Secondary outcomes: weight, blood pressure, hemoglobin A1C, glomerular filtration rate (GFR), and medication adherence compared to baseline. Inclusion criteria: Male or female Veterans between the ages of 18– 75 years with DM2 and ≥ 1 CV event and/or CKD and not on SGLT2i/GLP-1a. Exclusion criteria: Veterans with contraindications to SGLT2i/GLP-1 and/or a serious mental health disorder. Results: After baseline visit, all providers prescribed to 14/14 patients at least one of the medications with 12/14 prescribed SGLT2i and 2/14 prescribed GLP-1a. We found 13/14 (93%) patients to still be on at least one of the medications at 6 months. At 6 months compared to baseline, weight (216 lbs. ± 41 → 213 lbs. ± 39), blood pressure (141/76 ± 20/10 → 132/73 ± 17/10), A1C (7.7% ± 1.5% → 7.4% ± 0.8%) modestly decreased but GFR remained stable (64 mL/min ± 17 → 64 mL/min ± 19). Medication adherence was continued for all 13 patients (Medication possession ratio was ≥ 80%). Conclusion: DSS use was associated with increased SGLT2i/GLP-1a prescribing by VA primary care providers and medication adherence in Veterans DM2 patients with CVD/CKD. The DSS could help improve cardiorenal outcomes and guideline concordant in their DM2 patients in the future if larger studies can validate these findings. Clinical Trials Registration Number: NCT06142006.Keywords
This publication has 12 references indexed in Scilit:
- Cardiovascular outcomes trial data from EMPA‐REG OUTCOME , CAROLINA and CARMELINA : Assessment of a novel staging system for type 2 diabetesDiabetes, Obesity and Metabolism, 2023
- Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional studyBMC Primary Care, 2022
- Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans AffairsDiabetes Care, 2022
- CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countriesCardiovascular Diabetology, 2021
- Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology CommunityCirculation, 2021
- Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons LearnedAdvances in Chronic Kidney Disease, 2021
- TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?Diabetes, Metabolic Syndrome and Obesity, 2018
- A simple diabetes vascular severity staging instrument and its application to a Torres Strait Islander and Aboriginal adult cohort of north AustraliaBMC Health Services Research, 2012
- UISESS scale for staging and classifying clinical–epidemiological risk in type 2 diabetes mellitus and for establishing multidiscipinary preventive actionsPreventive Medicine, 2005
- Analyzing Variations in Medication Compliance Related to Individual Drug, Drug Class, and Prescribing PhysicianJournal of Managed Care Pharmacy, 1999